A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA 19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis
Phase of Trial: Phase III
Latest Information Update: 10 Nov 2016
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Roche
- 01 Aug 2016 Status changed from active, no longer recruiting to completed.
- 04 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Jul 2016.
- 04 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jul 2016.